Two phase III clinical trials evaluating the efficacy of MAGE-A3 peptide-based vaccines in the treatment of non-small-cell lung cancer (NSCLC) (n = 2272 patients) and melanoma (n = 1345 patients) have been performed. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.